Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PFIZER INCPFE · Entity 2863 | Executive Vice President | March 03, 2026 | March 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PFIZER INC
Report date March 03, 2026 · Filed March 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $26.58 · Expires 2031-03-03 | Direct | 194,883 |
Reported balance
After 2026-03-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-03 · Grant · Acquired 194,883 · Balance 194,883 F1: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2026 Filed Mar 5, 2026 22:24 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 194,883 | $0.00 Strike: $26.58 | $0.00 |
DisclosureSEC source: 0001225208-26-003308 · doc4.xml · derivative · entry 1 de Germay Alexandre · CIK 0002005574 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 194,883 Underlying: Common Stock · 194,883 shares Expires 2031-03-03 F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 18:57 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 371,824 | $0.00 Strike: $25.75 | $0.00 |
DisclosureSEC source: 0001225208-25-003074 · doc4.xml · derivative · entry 1 de Germay Alexandre · CIK 0002005574 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 371,824 Underlying: Common Stock · 371,824 shares Expires 2030-03-04 F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 21:58 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 79,111 | $0.00 Strike: $26.89 | $0.00 |
DisclosureSEC source: 0001225208-24-003196 · doc4.xml · derivative · entry 3 de Germay Alexandre · CIK 0002005574 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,111 Underlying: Common Stock · 79,111 shares Expires 2031-02-27 F3 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F3 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 21:58 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 89,533 | $0.00 Strike: $26.89 | $0.00 |
DisclosureSEC source: 0001225208-24-003196 · doc4.xml · derivative · entry 2 de Germay Alexandre · CIK 0002005574 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,533 Underlying: Common Stock · 89,533 shares Expires 2029-02-27 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 21:58 UTC | PFIZER INC PFE · Entity 2863 | GrantCommon Stock | 74,377 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-003196 · doc4.xml · nonDerivative · entry 1 de Germay Alexandre · CIK 0002005574 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,377 F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.